Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C viral dynamics.

T J Layden1, N P Lam, T E Wiley

  • 1Department of Medicine, Section of Digestive and Liver Diseases, University of Illinois, Chicago College of Medicine, Chicago, Illinois, USA.

Clinics in Liver Disease
|April 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An assessment of racial differences in the upper limits of normal ALT levels in children and the effect of obesity on elevated values.

Pediatric obesity·2016
Same author

Characterizing hepatitis B stigma in Chinese immigrants.

Journal of viral hepatitis·2012
Same author

Hepatocyte proliferation and hepatitis C virus kinetics during treatment.

Clinical pharmacology and therapeutics·2011
Same author

Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients.

Journal of viral hepatitis·2010
Same author

The prevalence and clinical correlates of elevated ALT levels in an urban Chinatown community.

Journal of viral hepatitis·2009
Same author

A novel anticancer agent ARC antagonizes HIV-1 and HCV.

Oncogene·2006
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Early and rapid viral clearance with interferon (IFN) therapy improves sustained virologic response rates in hepatitis C virus (HCV) patients. Standard IFN-alpha 2b doses are insufficient for genotypes 1a and 1b, necessitating optimized dosing and scheduling for better outcomes.

Area of Science:

  • Hepatology and Virology
  • Viral Kinetics and Immunology
  • Pharmacodynamics of Antiviral Therapy

Background:

  • Standard interferon-alpha 2b (IFN) dosages are inadequate for sustained viral load reduction in HCV genotypes 1a and 1b.
  • Understanding viral kinetics, similar to HIV and HBV, is crucial for optimizing HCV treatment.
  • Early viral clearance correlates with better sustained virologic response rates.

Purpose of the Study:

  • To analyze the viral kinetics of hepatitis C virus (HCV) under interferon (IFN) monotherapy.
  • To determine optimal initial IFN dosing and scheduling for HCV genotypes 1a and 1b.
  • To identify predictors of early viral clearance and sustained virologic response.

Main Methods:

  • Mathematical modeling and analysis of HCV RNA levels following IFN initiation.

Related Experiment Videos

  • Dose-ranging studies of IFN-alpha 2b to assess viral load reduction.
  • Evaluation of the relationship between viral decline phases and treatment outcomes.

    • Main Results:

    • IFN-alpha 2b induces a rapid, dose-dependent reduction in HCV RNA within 24-48 hours, indicating an effect on viral production.
    • HCV has a serum half-life of 3 hours and a high daily production rate.
    • The second, slower phase of viral decline, influenced by infected cell clearance, is a key predictor of early viral clearance.

    Conclusions:

    • Daily administration and sufficient initial doses of IFN are recommended for HCV genotypes 1a and 1b to achieve >95% viral reduction within 48 hours.
    • Further research is needed on higher IFN doses, the role of ribavirin, and viral kinetics in non-responders and other genotypes (2/3).
    • Optimizing IFN therapy based on viral kinetics can improve treatment efficacy and patient outcomes.